Last reviewed · How we verify
CD101
CD101 is a recombinant human monoclonal antibody targeting beta-glucan.
CD101 is a recombinant human monoclonal antibody targeting beta-glucan. Used for Treatment of invasive fungal disease.
At a glance
| Generic name | CD101 |
|---|---|
| Also known as | CD101 for Injection |
| Sponsor | Cidara Therapeutics Inc. |
| Drug class | Antifungal |
| Target | beta-glucan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
CD101 works by binding to beta-glucan, a polysaccharide component of the cell walls of fungi, thereby inhibiting the growth of fungal pathogens. This mechanism of action allows CD101 to selectively target and eliminate fungal infections, reducing the risk of invasive fungal disease.
Approved indications
- Treatment of invasive fungal disease
Common side effects
- Infusion-related reactions
- Infections
- Allergic reactions
Key clinical trials
- A Single Ascending Dose Study of CD101 IV in Healthy Subjects (PHASE1)
- A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
- CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (PHASE2)
- RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections (PHASE2)
- Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
- An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD101 CI brief — competitive landscape report
- CD101 updates RSS · CI watch RSS
- Cidara Therapeutics Inc. portfolio CI